

## Pemazyre (pemigatinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		_ MEMBER'S FIRST N	AME:	
	, chart notes or lab data, to		ny additional documentation that is on request). Information contained in  URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZI	P CODE:	
PATIENT INSURANCE ID NUMBER:				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):  AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PI	OFFICE CONTACT PERSON:	
		,		
MEDICATION OR MEDICAL	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY       ☐ RENEWAL       IF RENEWAL: DATE THERAPY INITIATED:         DURATION OF THERAPY (SPECIFIC DATES):				

Continued on next page.





## Pemazyre (pemigatinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER 2 TA21 NAME:	WIEWIBER'S FIRST I	NAIVIE:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:	ICD-10:			
<ul> <li>□ Unresectable, locally advanced cholangio</li> <li>□ Metastatic cholangiocarcinoma</li> <li>□ Relapsed or refractory myeloid/lymphoid</li> <li>□ Other diagnosis:</li> </ul>	i neoplasm(s) (MLNs) ICD-10:			
<b>3. REQUIRED CLINICAL INFORMATION:</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? $\Box$ Yes $\Box$ No				
Has patient had prior use of a selective	e FGFR inhibitor(Balversa(erdafitinib))?	□ Yes □ No		
For diagnosis of unresectable, locally advanced or metastatic cholangiocarcinma, please answer the following:  Does patient's cholangiocarcinoma have a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement?  See In No Please submit lab report.				
Has patient's disease progressed after at least one prior systemic treatment? $\Box$ Yes $\Box$ No Please submit documentation.				
Is patient ambulatory AND capable of	self-care? □ Yes □ No			
For diagnosis of relapsed or refractory myeloid/lymphoid neoplasms(MLNs), please answer the following:  Is patient's myeloid/lymphoid neoplasm positive for FGFR1 arrangement?   Yes   No Please submit lab report.				
Did patient relapse after stem cell transplant or after disease modifying therapy?   Yes  No Please submit documentation.				
Was patient not a candidate for stem con Please submit documentation.	ell transplantation or for other disease n	nodifying therapies?   Yes   No		
Does patient have graft versus host disc	ease?   Yes   No Please submit docu	mentation.		
Does patient have an ECOG status 0 to 2? □ Yes □ No Please submit documentation.				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				





## Pemazyre (pemigatinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

WEINBER 2 LAST NAINE:	MEMBER 2 FIR21 NAME:
Please note: Not all drugs/diagnosis are covered on all plans information is received.	s. This request may be denied unless all required
<b>ATTESTATION:</b> I attest the information provided is true and the Health Plan, insurer, Medical Group or its designees mainformation necessary to verify the accuracy of the information	y perform a routine audit and request the medical
Prescriber Signature or Electronic I.D. Verification:	Date:
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmissi you are not the intended recipient, you are hereby notified that any disclor of these documents is strictly prohibited. If you have received this inform and arrange for the return or destruction of these documents.	osure, copying, distribution, or action taken in reliance on the contents

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

